RU2003118583A - Набор с репинотаном - Google Patents
Набор с репинотаномInfo
- Publication number
- RU2003118583A RU2003118583A RU2003118583/15A RU2003118583A RU2003118583A RU 2003118583 A RU2003118583 A RU 2003118583A RU 2003118583/15 A RU2003118583/15 A RU 2003118583/15A RU 2003118583 A RU2003118583 A RU 2003118583A RU 2003118583 A RU2003118583 A RU 2003118583A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- repinotan
- kit according
- physiologically acceptable
- kit
- Prior art date
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 12
- YGYBFMRFXNDIPO-QGZVFWFLSA-N repinotan Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 YGYBFMRFXNDIPO-QGZVFWFLSA-N 0.000 claims 9
- 229950009693 repinotan Drugs 0.000 claims 9
- 239000002253 acid Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000003978 infusion fluid Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011975 tartaric acid Substances 0.000 claims 4
- 235000002906 tartaric acid Nutrition 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 2
- IGKYREHZJIHPML-UNTBIKODSA-N 2-[4-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methylamino]butyl]-1,1-dioxo-1,2-benzothiazol-3-one;hydron;chloride Chemical compound Cl.O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 IGKYREHZJIHPML-UNTBIKODSA-N 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 2
- 239000012491 analyte Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000011976 maleic acid Substances 0.000 claims 2
- 239000001630 malic acid Substances 0.000 claims 2
- 235000011090 malic acid Nutrition 0.000 claims 2
- 229940107700 pyruvic acid Drugs 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008151 electrolyte solution Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10058119A DE10058119A1 (de) | 2000-11-22 | 2000-11-22 | Pepinotan-Kit |
| DE10058119.6 | 2000-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003118583A true RU2003118583A (ru) | 2004-12-20 |
Family
ID=7664358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003118583/15A RU2003118583A (ru) | 2000-11-22 | 2001-11-09 | Набор с репинотаном |
Country Status (37)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004010050A1 (de) * | 2004-03-02 | 2005-09-22 | Bayer Healthcare Ag | Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US7439358B2 (en) * | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US8329695B2 (en) * | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| JP2016525532A (ja) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄異形成症候群の処置 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| DE19522088A1 (de) * | 1995-06-19 | 1997-01-02 | Bayer Ag | Benzisothiazolyl-substituierte Aminomethylchromane |
| DE19543476A1 (de) * | 1995-11-22 | 1997-05-28 | Troponwerke Gmbh & Co Kg | Verwendung von substituierten Aminomethyl-chromanen zur Behandlung von Schädel-Hirn-Trauma |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| DE19754573A1 (de) * | 1997-12-09 | 1999-06-10 | Bayer Ag | Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma |
| EP1062510A2 (en) * | 1998-03-10 | 2000-12-27 | Strategic Diagnostics Inc. | Integrated assay device and methods of production and use |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| DE19936281C2 (de) | 1999-08-02 | 2002-04-04 | Bayer Ag | Verfahren zur Gefriertrocknung |
-
2000
- 2000-11-22 DE DE10058119A patent/DE10058119A1/de not_active Ceased
-
2001
- 2001-11-09 HR HR20030490A patent/HRP20030490A2/hr not_active Application Discontinuation
- 2001-11-09 PT PT01989448T patent/PT1339403E/pt unknown
- 2001-11-09 EP EP01989448A patent/EP1339403B1/de not_active Expired - Lifetime
- 2001-11-09 WO PCT/EP2001/012968 patent/WO2002041881A2/de not_active Ceased
- 2001-11-09 NZ NZ525964A patent/NZ525964A/en unknown
- 2001-11-09 SK SK592-2003A patent/SK5922003A3/sk unknown
- 2001-11-09 KR KR10-2003-7006854A patent/KR20030096237A/ko not_active Withdrawn
- 2001-11-09 CZ CZ20031401A patent/CZ20031401A3/cs unknown
- 2001-11-09 AT AT01989448T patent/ATE284212T1/de not_active IP Right Cessation
- 2001-11-09 BR BR0115518-0A patent/BR0115518A/pt not_active IP Right Cessation
- 2001-11-09 ES ES01989448T patent/ES2234922T3/es not_active Expired - Lifetime
- 2001-11-09 CN CNA018221440A patent/CN1518446A/zh active Pending
- 2001-11-09 HU HU0303294A patent/HUP0303294A2/hu unknown
- 2001-11-09 RU RU2003118583/15A patent/RU2003118583A/ru not_active Application Discontinuation
- 2001-11-09 AU AU2002227912A patent/AU2002227912A1/en not_active Abandoned
- 2001-11-09 EE EEP200300242A patent/EE200300242A/xx unknown
- 2001-11-09 IL IL15597501A patent/IL155975A0/xx unknown
- 2001-11-09 DE DE2001504790 patent/DE50104790D1/de not_active Expired - Fee Related
- 2001-11-09 CN CNA2005100859302A patent/CN1715279A/zh active Pending
- 2001-11-09 CA CA002429310A patent/CA2429310A1/en not_active Abandoned
- 2001-11-09 JP JP2002544060A patent/JP2004517824A/ja active Pending
- 2001-11-09 SI SI200130270T patent/SI1339403T1/xx unknown
- 2001-11-09 MX MXPA03004499A patent/MXPA03004499A/es unknown
- 2001-11-09 PL PL36162801A patent/PL361628A1/xx not_active Application Discontinuation
- 2001-11-16 US US09/991,222 patent/US6605255B2/en not_active Expired - Fee Related
- 2001-11-19 UY UY27027A patent/UY27027A1/es not_active Application Discontinuation
- 2001-11-20 AR ARP010105412A patent/AR031761A1/es unknown
- 2001-11-20 MY MYPI20015310A patent/MY118345A/en unknown
- 2001-11-21 PE PE2001001162A patent/PE20020533A1/es not_active Application Discontinuation
- 2001-11-21 HN HN2001000262A patent/HN2001000262A/es unknown
- 2001-11-21 SV SV2001000744A patent/SV2003000744A/es unknown
- 2001-11-21 DO DO2001000293A patent/DOP2001000293A/es unknown
- 2001-11-22 GT GT200100236A patent/GT200100236A/es unknown
-
2003
- 2003-05-12 BG BG107803A patent/BG107803A/bg unknown
- 2003-05-15 NO NO20032212A patent/NO20032212D0/no not_active Application Discontinuation
- 2003-05-20 ZA ZA200303888A patent/ZA200303888B/en unknown
- 2003-05-21 EC EC2003004617A patent/ECSP034617A/es unknown
- 2003-05-22 US US10/444,820 patent/US20030203953A1/en not_active Abandoned
- 2003-05-22 MA MA27170A patent/MA26059A1/fr unknown
-
2005
- 2005-04-26 JP JP2005128270A patent/JP2005232189A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003118583A (ru) | Набор с репинотаном | |
| RU2006109467A (ru) | Способы лечения рака с использованием ингибиторов hdac | |
| EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
| JP2004505105A5 (enExample) | ||
| RU2014142000A (ru) | L-сахарный агент, очищающий толстую кишку, и его применения | |
| EA200500632A1 (ru) | Агрегат с повышенной способностью к деформации, содержащий по крайней мере три амфипатических соединения для лучшего проникновения через полунепроницаемые барьеры и для неинвазивного введения лекарственных средств in vivo в особенности через кожу | |
| RU2007122392A (ru) | Водная офтальмологическая суспензия кристаллического ребамипида | |
| RU95110937A (ru) | Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения | |
| RU2004101229A (ru) | Дейтерированные n-и альфа-замещенные аминоалкилэфиры дифенилакоксиуксуной кислоты, а также лекарственные средства, содержащие эти соединения | |
| RU2008152751A (ru) | Соли тримебутина и n-десметилтримебутина | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| RU2004102398A (ru) | Производные бензо[g]хинолина для лечения глаукомы и близорукости | |
| JP3643038B2 (ja) | メイラード反応阻害剤、ヒスタミン遊離抑制剤、活性酸素生成抑制剤及び過酸化脂質生成抑制剤 | |
| RU2006131553A (ru) | Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap | |
| JP2005519856A (ja) | 骨折を予防または治療するためのｌ−トレオン酸カルシウム | |
| RU2004129767A (ru) | Хинолиновые производные | |
| RU2009127858A (ru) | Фармацевтическая композиция, включающая алискирен и авосентан | |
| RU2005133478A (ru) | Применение производных карбамазепина для лечения возбуждения у пациентов, страдающих деменцией | |
| Stenbaek et al. | Hypotensive effect of methyldopa in renal failure associated with hypertension | |
| RU96100754A (ru) | N-[[1-[4-/4-фторфенокси/бутил]-4-пиперидинил]-n-метиламино]-2-бензотиазололы в качестве антиаритмических средств iii класса | |
| CA3224977A1 (en) | Agents and methods for modulating pathogen activity using ligands of complement receptor 3 | |
| RU2003104017A (ru) | Ингибиторы тромбина, содержащие аминоизохинолиновую группу | |
| EA199801015A1 (ru) | Производные пиперидинуксусной кислоты и их применение при лечении тромботических нарушений | |
| RU2006133903A (ru) | Способ лечения или профилактики остеопороза у индивидуумов с высоким обменом костной ткани | |
| Germain et al. | Failure of chelation therapy in lead nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070201 |